ARTICLE | Clinical News
Fosbretabulin: Phase II/III data
September 20, 2010 7:00 AM UTC
OxiGene Inc. (NASDAQ:OXGN), South San Francisco, Calif. Product: Fosbretabulin ( Combretastatin A4P, Zybrestat)) Business: Cancer Molecular target: Tubulin Description: A4 prodrug phosphatase-activa...